Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience
Identifieur interne : 000D86 ( Main/Corpus ); précédent : 000D85; suivant : 000D87Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience
Auteurs : Jordan J. Elm ; Cornelia Kamp ; Barbara C. Tilley ; Paulo Guimaraes ; Debbie Fraser ; Patricia Deppen ; Alicia Brocht ; Chris Weaver ; Susan BennettSource :
- Movement Disorders [ 0885-3185 ] ; 2007-04-30.
English descriptors
Abstract
Purpose: To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD. Methods: Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored. Results: Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40). Conclusions: Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21409
Links to Exploration step
ISTEX:E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title><author><name sortKey="Elm, Jordan J" sort="Elm, Jordan J" uniqKey="Elm J" first="Jordan J." last="Elm">Jordan J. Elm</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Guimaraes, Paulo" sort="Guimaraes, Paulo" uniqKey="Guimaraes P" first="Paulo" last="Guimaraes">Paulo Guimaraes</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Fraser, Debbie" sort="Fraser, Debbie" uniqKey="Fraser D" first="Debbie" last="Fraser">Debbie Fraser</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Deppen, Patricia" sort="Deppen, Patricia" uniqKey="Deppen P" first="Patricia" last="Deppen">Patricia Deppen</name><affiliation><mods:affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Brocht, Alicia" sort="Brocht, Alicia" uniqKey="Brocht A" first="Alicia" last="Brocht">Alicia Brocht</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Weaver, Chris" sort="Weaver, Chris" uniqKey="Weaver C" first="Chris" last="Weaver">Chris Weaver</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Bennett, Susan" sort="Bennett, Susan" uniqKey="Bennett S" first="Susan" last="Bennett">Susan Bennett</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21409</idno><idno type="url">https://api.istex.fr/document/E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title><author><name sortKey="Elm, Jordan J" sort="Elm, Jordan J" uniqKey="Elm J" first="Jordan J." last="Elm">Jordan J. Elm</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Guimaraes, Paulo" sort="Guimaraes, Paulo" uniqKey="Guimaraes P" first="Paulo" last="Guimaraes">Paulo Guimaraes</name><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</mods:affiliation></affiliation></author><author><name sortKey="Fraser, Debbie" sort="Fraser, Debbie" uniqKey="Fraser D" first="Debbie" last="Fraser">Debbie Fraser</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Deppen, Patricia" sort="Deppen, Patricia" uniqKey="Deppen P" first="Patricia" last="Deppen">Patricia Deppen</name><affiliation><mods:affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</mods:affiliation></affiliation></author><author><name sortKey="Brocht, Alicia" sort="Brocht, Alicia" uniqKey="Brocht A" first="Alicia" last="Brocht">Alicia Brocht</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Weaver, Chris" sort="Weaver, Chris" uniqKey="Weaver C" first="Chris" last="Weaver">Chris Weaver</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Bennett, Susan" sort="Bennett, Susan" uniqKey="Bennett S" first="Susan" last="Bennett">Susan Bennett</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-30">2007-04-30</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="822">822</biblScope><biblScope unit="page" to="827">827</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227</idno><idno type="DOI">10.1002/mds.21409</idno><idno type="ArticleID">MDS21409</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Morisky score</term><term>Parkinson's disease</term><term>clinical trial</term><term>treatment adherence</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD. Methods: Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored. Results: Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40). Conclusions: Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jordan J. Elm MA</name><affiliations><json:string>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</json:string></affiliations></json:item><json:item><name>Cornelia Kamp MBA</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Barbara C. Tilley PhD</name><affiliations><json:string>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</json:string></affiliations></json:item><json:item><name>Paulo Guimaraes PhD</name><affiliations><json:string>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</json:string></affiliations></json:item><json:item><name>Debbie Fraser BS, CCRP</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Patricia Deppen RN, MA</name><affiliations><json:string>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</json:string></affiliations></json:item><json:item><name>Alicia Brocht BA</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Chris Weaver CCRP</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Susan Bennett AAS</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment adherence</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Morisky score</value></json:item></subject><articleId><json:string>MDS21409</json:string></articleId><language><json:string>eng</json:string></language><abstract>Purpose: To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD. Methods: Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored. Results: Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40). Conclusions: Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>5.913</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1298</abstractCharCount><pdfWordCount>3645</pdfWordCount><pdfCharCount>23386</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>189</abstractWordCount></qualityIndicators><title>Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title><corporate><json:item><name>NINDS NET‐PD Investigators and Coordinators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>827</last><first>822</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21409</json:string></doi><id>E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>NIH (National Institute of Neurological Disorders and Stroke) - No. U01NS043127; No. U01NS043128; No. U10NS44415 through 44555;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title><author><orgName>NINDS NET‐PD Investigators and Coordinators</orgName></author><author><persName><forename type="first">Jordan J.</forename><surname>Elm</surname></persName><roleName type="degree">MA</roleName><note type="correspondence"><p>Correspondence: Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St., Suite 303, P.O. Box 250835 Charleston, SC 29425</p></note><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation></author><author><persName><forename type="first">Cornelia</forename><surname>Kamp</surname></persName><roleName type="degree">MBA</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Barbara C.</forename><surname>Tilley</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation></author><author><persName><forename type="first">Paulo</forename><surname>Guimaraes</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation></author><author><persName><forename type="first">Debbie</forename><surname>Fraser</surname></persName><roleName type="degree">BS, CCRP</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Patricia</forename><surname>Deppen</surname></persName><roleName type="degree">RN, MA</roleName><affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</affiliation></author><author><persName><forename type="first">Alicia</forename><surname>Brocht</surname></persName><roleName type="degree">BA</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Chris</forename><surname>Weaver</surname></persName><roleName type="degree">CCRP</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Susan</forename><surname>Bennett</surname></persName><roleName type="degree">AAS</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-30"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="822">822</biblScope><biblScope unit="page" to="827">827</biblScope></imprint></monogr><idno type="istex">E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227</idno><idno type="DOI">10.1002/mds.21409</idno><idno type="ArticleID">MDS21409</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Purpose: To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD. Methods: Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored. Results: Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40). Conclusions: Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>treatment adherence</term></item><item><term>clinical trial</term></item><item><term>Morisky score</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-10-23">Received</change><change when="2006-12-22">Registration</change><change when="2007-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v22:6</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2007-04-30">30 April 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="90" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21409</doi><idGroup><id type="unit" value="MDS21409"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-10-23"></event><event type="manuscriptRevised" date="2006-12-19"></event><event type="manuscriptAccepted" date="2006-12-22"></event><event type="firstOnline" date="2007-03-13"></event><event type="publishedOnlineFinalForm" date="2007-04-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-03-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">822</numbering><numbering type="pageLast">827</numbering></numberingGroup><correspondenceTo>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St., Suite 303, P.O. Box 250835 Charleston, SC 29425</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21409.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="30"></count><count type="wordTotal" number="4095"></count></countGroup><titleGroup><title type="main" xml:lang="en">Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title><title type="short" xml:lang="en">NET‐PD Treatment Adherence</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jordan J.</givenNames><familyName>Elm</familyName><degrees>MA</degrees></personName><contactDetails><email>elmj@musc.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Cornelia</givenNames><familyName>Kamp</familyName><degrees>MBA</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Barbara C.</givenNames><familyName>Tilley</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Paulo</givenNames><familyName>Guimaraes</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Debbie</givenNames><familyName>Fraser</familyName><degrees>BS, CCRP</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Patricia</givenNames><familyName>Deppen</familyName><degrees>RN, MA</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Alicia</givenNames><familyName>Brocht</familyName><degrees>BA</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Chris</givenNames><familyName>Weaver</familyName><degrees>CCRP</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Susan</givenNames><familyName>Bennett</familyName><degrees>AAS</degrees></personName></creator><creator xml:id="au10" creatorRole="author"><groupName>NINDS NET‐PD Investigators and Coordinators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">treatment adherence</keyword><keyword xml:id="kwd3">clinical trial</keyword><keyword xml:id="kwd4">Morisky score</keyword></keywordGroup><fundingInfo><fundingAgency>NIH (National Institute of Neurological Disorders and Stroke)</fundingAgency><fundingNumber>U01NS043127</fundingNumber><fundingNumber>U01NS043128</fundingNumber><fundingNumber>U10NS44415 through 44555</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Purpose</title><p>To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD.</p></section><section xml:id="abs1-2"><title type="main">Methods</title><p>Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored.</p></section><section xml:id="abs1-3"><title type="main">Results</title><p>Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40).</p></section><section xml:id="abs1-4"><title type="main">Conclusions</title><p>Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>NET‐PD Treatment Adherence</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience</title></titleInfo><name type="personal"><namePart type="given">Jordan J.</namePart><namePart type="family">Elm</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation><description>Correspondence: Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St., Suite 303, P.O. Box 250835 Charleston, SC 29425</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cornelia</namePart><namePart type="family">Kamp</namePart><namePart type="termsOfAddress">MBA</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara C.</namePart><namePart type="family">Tilley</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paulo</namePart><namePart type="family">Guimaraes</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Debbie</namePart><namePart type="family">Fraser</namePart><namePart type="termsOfAddress">BS, CCRP</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patricia</namePart><namePart type="family">Deppen</namePart><namePart type="termsOfAddress">RN, MA</namePart><affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alicia</namePart><namePart type="family">Brocht</namePart><namePart type="termsOfAddress">BA</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chris</namePart><namePart type="family">Weaver</namePart><namePart type="termsOfAddress">CCRP</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Susan</namePart><namePart type="family">Bennett</namePart><namePart type="termsOfAddress">AAS</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>NINDS NET‐PD Investigators and Coordinators</namePart><description>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South CarolinaDepartment of Neurology, University of Rochester, Rochester, New YorkDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-04-30</dateIssued><dateCaptured encoding="w3cdtf">2006-10-23</dateCaptured><dateValid encoding="w3cdtf">2006-12-22</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">30</extent><extent unit="words">4095</extent></physicalDescription><abstract lang="en">Purpose: To compare the Morisky medication adherence questionnaire to pill counts as measures of adherence in the NET‐PD futility clinical trials. Background: Like in other chronic diseases, non‐adherence with medications occurs in Parkinson's disease (PD), although nonadherence has not been of significant concern in most PD clinical trials. The most common approach to assessment is to do a pill count at each visit. The simple, 4‐question Morisky medication adherence questionnaire may provide an alternative approach to monitoring treatment adherence in PD. Methods: Adherence data from two NET‐PD Phase II clinical trials enrolling a total of 413 participants were analyzed. The association between demographic and clinical characteristics and adherence was explored. Results: Ninety‐percent of participants took 80% or more of the study drug. However, the Morisky medication adherence questionnaires showed 56% report high and 44% report medium adherence. Agreement between the two measures is fair (ICC = 0.40). Conclusions: Overall adherence as assessed by pill count appears high. The Morisky medication adherence questionnaire may be useful in PD clinical trials, since it is moderately correlated to pill count and may be more sensitive to nonadherence. © 2007 Movement Disorder Society</abstract><note type="funding">NIH (National Institute of Neurological Disorders and Stroke) - No. U01NS043127; No. U01NS043128; No. U10NS44415 through 44555; </note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>treatment adherence</topic><topic>clinical trial</topic><topic>Morisky score</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>822</start><end>827</end><total>6</total></extent></part></relatedItem><identifier type="istex">E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227</identifier><identifier type="DOI">10.1002/mds.21409</identifier><identifier type="ArticleID">MDS21409</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E4796225A5AE3C63A0A32A25E8F44AD5BA9E7227
|texte= Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience
}}
| This area was generated with Dilib version V0.6.23. |  |